ScoreWhy is Mankind Pharma Ltd ?
1
High Management Efficiency with a high ROCE of 20.79%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.74 times
3
Healthy long term growth as Operating profit has grown by an annual rate 20.15%
4
Positive results in Mar 26
- OPERATING PROFIT TO INTEREST(Q) Highest at 6.56 times
- OPERATING PROFIT TO NET SALES(Q) Highest at 27.01%
- PBT LESS OI(Q) Highest at Rs 568.04 cr.
5
High Institutional Holdings at 24.7%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Market Beating performance in long term as well as near term
- Along with generating 4.06% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Mankind Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Mankind Pharma for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Mankind Pharma
5.09%
0.16
25.76%
Sensex
-6.29%
-0.42
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.73%
EBIT Growth (5y)
20.15%
EBIT to Interest (avg)
27.35
Debt to EBITDA (avg)
1.33
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.79
Tax Ratio
16.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.70%
ROCE (avg)
20.58%
ROE (avg)
15.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
49
Industry P/E
34
Price to Book Value
6.12
EV to EBIT
38.12
EV to EBITDA
28.79
EV to Capital Employed
5.06
EV to Sales
7.29
PEG Ratio
33.10
Dividend Yield
0.04%
ROCE (Latest)
13.26%
ROE (Latest)
12.39%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING PROFIT TO INTEREST(Q)
Highest at 6.56 times
OPERATING PROFIT TO NET SALES(Q)
Highest at 27.01%
PBT LESS OI(Q)
Highest at Rs 568.04 cr.
PBDIT(Q)
Highest at Rs 929.88 cr.
PAT(Q)
Highest at Rs 574.01 cr.
EPS(Q)
Highest at Rs 13.43
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 482.77 cr
Loading Valuation Snapshot...
Here's what is working for Mankind Pharma
Operating Profit to Interest - Quarterly
Highest at 6.56 times and Grown
each quarter in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Operating Profit Margin - Quarterly
Highest at 27.01% and Grown
each quarter in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 568.04 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 929.88 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 568.04 cr has Grown at 25.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 451.01 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 574.01 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 574.01 cr has Grown at 22.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 467.41 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 13.43
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Mankind Pharma
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 482.77 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
